Clinical Trials Browser

HER2-positive Breast Cancer

Breast Neoplasms

Colorectal Neoplasms

Breast Neoplasms

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

HER2-positive Breast Cancer

Lymphoma, Non-Hodgkin, Multiple Myeloma

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Brain Neoplasms

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

HER2-positive Metastatic Breast Cancer

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Colorectal Neoplasms

Adenocarcinoma, Rectal Neoplasms

Colorectal Neoplasms

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Breast Neoplasms, Meningeal Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Breast Neoplasms

Breast Neoplasms

Colonic Neoplasms

Brain Neoplasms, Neoplasm Metastasis

Clinical Trials

BREnnA

HER2CLIMB-05

MOUNTAINEER-03

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

TAPUR

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

CAPTUR

JAZMINE

HER2CLIMB-04

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

BRIDGET

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

I-SPY

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

H3RAKLES

A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain

MK-1022-009

ERASE-CRC

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)